- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01919814
A Short-Term Appetite Suppression Trial Using Appethyl™: The Pizza (Pizza)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Four hours after breakfast a small amount of liquid to drink will be given to a participant that will contain either the Appethyl™ or placebo. Participants will be given a lunch of about 750 calories and 40% fat prepared by the Metabolic Kitchen and be asked to eat all of it. Participants will have food choice testing performed 4 hours after starting their lunch meal. This will be done in two ways. Participants will be given a list of two foods that are made of carbohydrate like bread and pretzels and be asked which is most preferred. Participants will also be given a list of foods that differ in the amounts of fat, carbohydrate and protein that they contain and will be asked to mark the ones that appeal to them.
Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pennington Biomedical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- You are a male or female aged 18 to 65 years.
- You have a BMI (a number calculated from your height and weight) between 25-35 kg/m2, inclusive.
- Your waist circumference is over 35 inches.
Exclusion Criteria:
- You have been on a diet for weight loss in the last 2 months.
- You are being treated for blood pressure, diabetes, heart disease, rheumatoid arthritis, or blood vessel disease.
- You have a psychotic illness.
- You have other chronic diseases like an inflammatory bowel disease such as Crohn's disease or ulcerative colitis.
- You have a dysfunction of your gastrointestinal tract.
- You have food allergies.
- You have rheumatoid arthritis with inflammation.
- You have chronic constipation.
- You are taking any products to lose weight such as medication for obesity or non-prescription medications for weight loss.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Appethyl™, then Placebo
Participants receive Appethyl™ liquid once four hours after breakfast.
After a washout period of at least one week, they received the placebo drink once four hours after breakfast.
|
Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™.
They will not know which they are getting and it will be decided randomly, like flipping a coin.
Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes.
Participants are not expected to eat all of the pizza.
Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid).
Participants will not know which they are getting and it will be decided randomly, like flipping a coin.
Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes.
They are not expected to eat all of the pizza.
|
|
Placebo Comparator: Placebo, then Appethyl™
Participants receive the placebo drink once four hours after breakfast.
After a washout period of at least one week, they received Appethyl™ liquid once four hours after breakfast.
|
Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™.
They will not know which they are getting and it will be decided randomly, like flipping a coin.
Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes.
Participants are not expected to eat all of the pizza.
Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid).
Participants will not know which they are getting and it will be decided randomly, like flipping a coin.
Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes.
They are not expected to eat all of the pizza.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in Pizza Consumed During Two Meals
Time Frame: 5 hours after lunch (9 hours after administration of Appethyl from the morning)
|
Four hours after breakfast administration of Appethyl™ or placebo(inactive liquid) is given.
You will be presented with a standard lunch and then (5 hours after lunch) pizza in a quantity of more than you could reasonably be expected to eat 5 hours after the start of your lunch meal and be asked to eat to your satisfaction over 30 minutes.
You are not expected to eat all of the pizza.
|
5 hours after lunch (9 hours after administration of Appethyl from the morning)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of Appetite
Time Frame: 30 minutes, 60 minutes, 120 minutes after consuming the drug or placebo
|
The Visual Analogue scale allows you to mark a vertical line across the horizontal scale on how hungry you are or not.
The Visual Analogue scale was used to evaluate hunger, fullness, longing for food, prospective intake, satisfaction, desire for salty food, desire for savory food, thirst, and desire for sweet food.
The scale ranged from 0 to 100mm; the higher values indicated greater outcomes.
|
30 minutes, 60 minutes, 120 minutes after consuming the drug or placebo
|
|
Evaluation of Satiety by Means of Visual Analogue Scale
Time Frame: 30 minutes, 60 minutes, 120 minutes after consuming the drug or placebo
|
The Visual Analogue scale allows you to mark a vertical line across the horizontal scale on how hungry you are or not.
The Visual Analogue scale was used to evaluate hunger, fullness, longing for food, prospective intake, satisfaction, desire for salty food, desire for savory food, thirst, and desire for sweet food.
The scale ranged from 0 to 100mm; the higher values indicated greater outcomes.
|
30 minutes, 60 minutes, 120 minutes after consuming the drug or placebo
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Frank Greenway, MD, Pennington Biomedical Research Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PBRC 13022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
Clinical Trials on Appethyl™
-
University of CopenhagenLund University; Greenleaf Medical AB, Lund, SwedenTerminatedPreDiabetes | Overweight and ObesityDenmark
-
Region SkaneLund UniversityCompletedObesity | Metabolic Syndrome
-
Region SkaneLund UniversityCompletedGlucose Intolerance
-
BaroNova, Inc.Completed
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUnknownBrain Damage, Chronic | Cerebellar Cognitive Affective Syndrome | Cerebellar Mutism
-
Asklepios Kliniken Hamburg GmbHUniversity of KielCompletedAirway Management | Laryngeal Mask Airway | Fibreoptic Intubation
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...Active, not recruitingHydrocephalus | Hydrocephalus, CommunicatingArgentina
-
Medtronic CardiovascularCompletedAortic AneurysmGermany, United States, Netherlands, Switzerland, United Kingdom, New Zealand, Spain, Australia, Italy, Sweden, France, Austria, Slovakia
-
Gülçin Özalp GerçekerCompletedCatheter Complications | Catheter LeakageTurkey
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalUnknownTemporal Lobe Epilepsy